ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 8-K: ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
ADC Therapeutics | DEF 14A: Definitive information statements
ADC Therapeutics | DEFA14A: Others
ADC Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
ADC Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
ADC Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
ADC Therapeutics | 8-K: ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ADC Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
ADC Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
No Data